NICE technology appraisal TA875 (semaglutide 2.4 mg, Wegovy) recommends semaglutide as an option for managing overweight and obesity in adults when all of the following criteria are met: [2] [3] BMI of at least 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease), or a BMI of 3034.9 kg/m in specific circumstances defined within the appraisal (for example, recent-onset type 2 diabetes) Treatment is delivered as part of a specialist multidisciplinary weight management service (Tier 3 or equivalent) Use is recommended for a maximum of two years under current NHS commissioning arrangements NICE technology appraisal TA1026 addresses tirzepatide (Mounjaro) for weight management, recommending it for adults with a BMI of 35 kg/m or above alongside at least one weight-related comorbidity, again within a specialist service context

medbasic.co.uk MediSupplies: Offers a variety of high-quality sterile needles and syringes suitable for different medical needs
it can be found in trace amounts in our environment and accumulate in our body over time
Semaglutide fatigue often relates to reduced caloric intake as appetite decreases
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP -1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP -1 receptor agonists
One of the possible reasons for this is that metformin inhibits sodium-glucose cotransporter1 (SGLT1) on small intestinal epithelial cells, decreasing the intra- and extracellular Na + concentration gradient, thereby inhibiting intestinal glucose absorption and increasing glucose utilization (Lenzen et al., 1996